467 related articles for article (PubMed ID: 22752818)
1. Plasma homocysteine level and its relationship to clinical profile in Parkinson's disease patients at the Lagos University Teaching Hospital.
Ojo OO; Oladipo OO; Ojini FI; Sanya EO; Danesi MA; Okubadejo NU
West Afr J Med; 2011; 30(5):319-24. PubMed ID: 22752818
[TBL] [Abstract][Full Text] [Related]
2. Serum homocysteine and physical exercise in patients with Parkinson's disease.
Nascimento CM; Stella F; Garlipp CR; Santos RF; Gobbi S; Gobbi LT
Psychogeriatrics; 2011 Jun; 11(2):105-12. PubMed ID: 21707858
[TBL] [Abstract][Full Text] [Related]
3. Hyperhomocysteinemia in levodopa-treated patients with Parkinson's disease dementia.
Zoccolella S; dell'Aquila C; Abruzzese G; Antonini A; Bonuccelli U; Canesi M; Cristina S; Marchese R; Pacchetti C; Zagaglia R; Logroscino G; Defazio G; Lamberti P; Livrea P
Mov Disord; 2009 May; 24(7):1028-33. PubMed ID: 19353704
[TBL] [Abstract][Full Text] [Related]
4. Plasma homocysteine levels and Parkinson disease: disease progression, carotid intima-media thickness and neuropsychiatric complications.
Hassin-Baer S; Cohen O; Vakil E; Sela BA; Nitsan Z; Schwartz R; Chapman J; Tanne D
Clin Neuropharmacol; 2006; 29(6):305-11. PubMed ID: 17095893
[TBL] [Abstract][Full Text] [Related]
5. Effects of levodopa and COMT inhibitors on plasma homocysteine in Parkinson's disease patients.
Lamberti P; Zoccolella S; Iliceto G; Armenise E; Fraddosio A; de Mari M; Livrea P
Mov Disord; 2005 Jan; 20(1):69-72. PubMed ID: 15390046
[TBL] [Abstract][Full Text] [Related]
6. Hyperhomocysteinemia due to levodopa treatment as a risk factor for osteoporosis in patients with Parkinson's disease.
Lee SH; Kim MJ; Kim BJ; Kim SR; Chun S; Kim HK; Ryu JS; Kim GS; Lee MC; Chung SJ; Koh JM
Calcif Tissue Int; 2010 Feb; 86(2):132-41. PubMed ID: 20049422
[TBL] [Abstract][Full Text] [Related]
7. Methylenetetrahydrofolate reductase polymorphisms and plasma homocysteine in levodopa-treated and non-treated Parkinson's disease patients.
Yuan RY; Sheu JJ; Yu JM; Hu CJ; Tseng IJ; Ho CS; Yeh CY; Hung YL; Chiang TR
J Neurol Sci; 2009 Dec; 287(1-2):64-8. PubMed ID: 19786283
[TBL] [Abstract][Full Text] [Related]
8. Association of homocysteine with ventricular dilatation and brain atrophy in Parkinson's disease.
Sapkota S; Gee M; Sabino J; Emery D; Camicioli R
Mov Disord; 2014 Mar; 29(3):368-74. PubMed ID: 24395213
[TBL] [Abstract][Full Text] [Related]
9. Homocysteine is not associated with global motor or cognitive measures in nondemented older Parkinson's disease patients.
Camicioli RM; Bouchard TP; Somerville MJ
Mov Disord; 2009 Jan; 24(2):176-82. PubMed ID: 18951534
[TBL] [Abstract][Full Text] [Related]
10. Clinical significance of homocysteine (hcy) on dementia in Parkinson's disease (PD).
Song IU; Kim JS; Park IS; Kim YD; Cho HJ; Chung SW; Lee KS
Arch Gerontol Geriatr; 2013; 57(3):288-91. PubMed ID: 23706974
[TBL] [Abstract][Full Text] [Related]
11. The effect of levodopa benserazide hydrochloride on homocysteinemia levels in patients with Parkinson's disease and treatment of hyperhomocysteinemia.
Guo G; Xu S; Cao LD; Wu QY
Eur Rev Med Pharmacol Sci; 2016 Jun; 20(11):2409-12. PubMed ID: 27338068
[TBL] [Abstract][Full Text] [Related]
12. [Effects of entacapone on plasma homocysteine in Parkinson's disease patients on levodopa].
Zhao P; Yang JF; Liu W; Wang Y; Sun YN; Li Q; Zhang W; Zhang BS
Zhonghua Yi Xue Za Zhi; 2013 Feb; 93(7):512-5. PubMed ID: 23660319
[TBL] [Abstract][Full Text] [Related]
13. Homocysteine Levels in Parkinson's Disease: Is Entacapone Effective?
Kocer B; Guven H; Comoglu SS
Biomed Res Int; 2016; 2016():7563705. PubMed ID: 27493964
[TBL] [Abstract][Full Text] [Related]
14. Hyperhomocysteinemia in L-dopa treated Parkinson's disease patients: effect of cobalamin and folate administration.
Lamberti P; Zoccolella S; Armenise E; Lamberti SV; Fraddosio A; de Mari M; Iliceto G; Livrea P
Eur J Neurol; 2005 May; 12(5):365-8. PubMed ID: 15804266
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease.
Adamiak U; Kaldonska M; Klodowska-Duda G; Wyska E; Safranow K; Bialecka M; Gawronska-Szklarz B
Clin Neuropharmacol; 2010 May; 33(3):135-41. PubMed ID: 20216409
[TBL] [Abstract][Full Text] [Related]
16. Levodopa-induced hyperhomocysteinaemia in Parkinson's disease.
Yasui K; Nakaso K; Kowa H; Takeshima T; Nakashima K
Acta Neurol Scand; 2003 Jul; 108(1):66-7. PubMed ID: 12807397
[No Abstract] [Full Text] [Related]
17. Neuropathy and levodopa in Parkinson's disease: evidence from a multicenter study.
Ceravolo R; Cossu G; Bandettini di Poggio M; Santoro L; Barone P; Zibetti M; Frosini D; Nicoletti V; Manganelli F; Iodice R; Picillo M; Merola A; Lopiano L; Paribello A; Manca D; Melis M; Marchese R; Borelli P; Mereu A; Contu P; Abbruzzese G; Bonuccelli U
Mov Disord; 2013 Sep; 28(10):1391-7. PubMed ID: 23836370
[TBL] [Abstract][Full Text] [Related]
18. Elevated plasma homocysteine level in patients with Parkinson disease: motor, affective, and cognitive associations.
O'Suilleabhain PE; Sung V; Hernandez C; Lacritz L; Dewey RB; Bottiglieri T; Diaz-Arrastia R
Arch Neurol; 2004 Jun; 61(6):865-8. PubMed ID: 15210523
[TBL] [Abstract][Full Text] [Related]
19. Association of COMT, MTHFR, and SLC19A1(RFC-1) polymorphisms with homocysteine blood levels and cognitive impairment in Parkinson's disease.
Białecka M; Kurzawski M; Roszmann A; Robowski P; Sitek EJ; Honczarenko K; Gorzkowska A; Budrewicz S; Mak M; Jarosz M; Gołąb-Janowska M; Koziorowska-Gawron E; Droździk M; Sławek J
Pharmacogenet Genomics; 2012 Oct; 22(10):716-24. PubMed ID: 22890010
[TBL] [Abstract][Full Text] [Related]
20. Hyperhomocysteinemia and methylenetetrahydrofolate reductase polymorphism in patients with Parkinson's disease.
Religa D; Czyzewski K; Styczynska M; Peplonska B; Lokk J; Chodakowska-Zebrowska M; Stepien K; Winblad B; Barcikowska M
Neurosci Lett; 2006 Aug; 404(1-2):56-60. PubMed ID: 16787708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]